What are the recommended diagnostic steps and management strategies, including transfusion and iron‑chelation therapy, for children with thalassemia?

Management of Pediatric Thalassemia

Children with transfusion-dependent beta-thalassemia major should begin regular blood transfusions as early as possible to maintain hemoglobin around 10 g/dL, combined with lifelong iron chelation therapy to prevent fatal cardiac iron overload, which is the leading cause of death in this population. 1

Diagnostic Approach

Initial Laboratory Evaluation

• Complete blood count revealing microcytic anemia (low MCV) with hemoglobin typically <7 g/dL in untreated thalassemia major 2, 3
• Blood smear showing target cells, nucleated red blood cells, and hypochromic microcytic red cells 2
• Hemoglobin electrophoresis to quantify HbA2 and HbF levels, confirming beta-globin chain abnormalities 3
• DNA analysis (genetic testing) to identify specific beta-globin gene mutations for definitive diagnosis and genetic counseling 2, 3

Prenatal Diagnosis

• Genetic testing of amniotic fluid or chorionic villus sampling for at-risk pregnancies, which can detect single point mutations with high reliability 4
• This allows prevention of thalassemia major births through informed reproductive decisions 3

Transfusion Therapy

Transfusion Protocol

• Maintain pre-transfusion hemoglobin at approximately 10 g/dL to minimize cardiac workload and suppress ineffective erythropoiesis 1
• Regular transfusions (typically every 2-4 weeks) are required for thalassemia major patients starting from infancy when severe anemia manifests 1, 5
• This strategy reduces chronic cardiac output demands and decreases compensatory cardiac hypertrophy, making the heart less susceptible to iron toxicity 1

Monitoring During Transfusion

• Track total transfusion burden as each unit contains approximately 200 mg of iron 1
• Assess for transfusion-related complications including alloimmunization and transfusion reactions 5

Iron Chelation Therapy

Critical Importance

Iron overload from chronic transfusions causes heart disease (the leading cause of death), liver disease, and endocrine dysfunction including hypothyroidism and diabetes. 1 Even without transfusions, thalassemia intermedia patients may develop iron overload from increased gastrointestinal absorption 1

Chelation Initiation and Monitoring

• Begin iron chelation after 10-20 transfusions or when serum ferritin exceeds 1000 ng/mL 1
• Target serum ferritin around 1000 ng/mL to prevent organ damage while avoiding over-chelation 5
• Monitor serum ferritin every 3-6 months, recognizing that ferritin >1000 ng/mL significantly worsens survival with a 30% increase in hazard for every 500 ng/mL increase 1

Chelation Options

For cardiac iron overload without overt dysfunction:

• Deferiprone shows superior efficacy versus deferoxamine for cardiac iron removal 1
• Combined deferiprone with deferoxamine is superior to deferoxamine alone 1
• Deferasirox is equivalent to deferoxamine for general iron chelation 1

For severe iron overload (ferritin >2500 µg/dL):

• Combination oral chelation with deferasirox (40 mg/kg/day) plus deferiprone effectively reduces iron burden in heavily overloaded children, with significant ferritin reduction from 4277 to 2985 µg/dL over 12 months 6

Common Pitfalls in Iron Management

• Normal serum ferritin does not exclude liver iron loading in certain genetic variants; consider liver MRI for accurate assessment 1
• Cardiac MRI (T2*) provides superior assessment of cardiac iron compared to serum ferritin alone 1
• Even low amounts of iron can amplify toxic effects of other hepatotoxins (alcohol, viruses), accelerating liver fibrosis 1

Curative Treatment Options

Hematopoietic Stem Cell Transplantation (HSCT)

For children with an HLA-matched sibling donor, HSCT should be performed as early as possible before iron-related complications develop, ideally before age 14 years. 1

Transplant Outcomes

• Overall survival 91% and disease-free survival 83% in modern series of matched sibling donor transplants 1
• Transplant-related mortality has fallen to ≤5% in young, low-risk children with matched sibling donors 1
• Age <14 years achieves 96% disease-free survival versus 74% in older patients 1

Risk Stratification

• Patient status at transplantation (Pesaro risk score) is the critical predictor of outcome 1
• Three key risk factors: age, hepatomegaly >2 cm, and inadequate chelation causing liver fibrosis 1
• Adequate pre-transplant chelation is essential as elevated ferritin increases treatment-related mortality and veno-occlusive disease risk 1

Donor Selection

• HLA-matched sibling donors provide best outcomes (25-30% of patients have this option) 1
• Cord blood from HLA-matched siblings shows 96% overall survival and 81% disease-free survival with lower GVHD rates (10% acute, 5% chronic) 1
• Alternative donors (matched unrelated, haploidentical) have inferior results and should be considered within clinical trials 1

Emerging Therapies

• Gene therapy has achieved first successful cases and represents a promising future curative option, though currently limited to specialized centers 1
• Hematopoietic stem cell transplantation remains the only widely available curative approach globally 1

Management of Thalassemia Intermedia

For non-transfusion-dependent patients:

• Folic acid supplementation to support increased erythropoiesis 2, 7
• Hydroxyurea to increase fetal hemoglobin production in selected cases 7, 4
• Splenectomy for symptomatic splenomegaly or hypersplenism 7, 4
• Iron chelation may still be required even without transfusions due to increased gastrointestinal iron absorption 1, 7
• Monitor for complications including skeletal deformities, extramedullary hematopoiesis, and endocrine dysfunction 7

Infection Prevention

Hepatitis B Vaccination

• All thalassemia patients should receive HBV vaccination before initiating transfusion therapy in countries without universal infant immunization programs 1
• Steady sexual partners of HBV-infected patients require vaccination 1
• Infants born to HBsAg-positive mothers need hepatitis B immune globulin and vaccine immediately after birth 1

Hepatitis C Screening

• Enzyme immunoassay for anti-HCV antibodies with confirmatory HCV RNA testing by PCR 1
• Approximately 50% of anti-HCV-positive thalassemia patients have detectable HCV RNA (active infection) 1
• HCV genotyping guides antiviral therapy decisions 1

Long-Term Complications Management

Cardiac Monitoring

• Regular cardiac MRI (T2)* to detect early cardiac iron deposition before dysfunction develops 1
• Echocardiography to assess ventricular function and detect dilated cardiomyopathy from chronic anemia 1
• Early cardiac disease is easier and safer to treat than advanced heart failure 1

Endocrine Surveillance

• Screen for hypothyroidism, diabetes, and hypogonadism from iron-mediated endocrine gland damage 1
• Monitor growth and pubertal development in children 7, 5

Hepatic Assessment

• Liver enzymes and assessment for fibrosis/cirrhosis 1
• Screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis 1